In a move that will delight Novo Nordisk and Eli Lilly, the FDA has sent warning letters to 30 telehealth companies, accusing them of illegally marketing compounded GLP-1 agonist formulations. The ...

The World Anti-Doping Agency (WADA) said it is now monitoring GLP-1 use among elite athletes, including at the Winter Olympics in Italy. Being ‘monitored’ does not mean a substance is prohibited; ...